Gonorrhea Market Epidemiology Report 2025-2035 | Drug Pipeline, Therapies, and Regional Outlook

According to the IMARC Group, the gonorrhea market size reached a value of USD 1.13 billion in 2024. Looking forward, the top 7 major markets are expected to reach USD 1.46 billion by 2035, exhibiting a growth rate (CAGR) of 2.39% during 2025-2035. This can be attributed to the growing use of combination treatments, which include many antibiotics, due to their several benefits, such as better patient outcomes, less risk of resistance development, and increased therapeutic efficacy.

Gonorrhea refers to a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. The gonorrhea market is experiencing significant growth due to several key factors. Primarily, the increasing prevalence of gonorrhea infections is a major driver, as it creates a substantial demand for effective treatments and diagnostic tools. Furthermore, the growing awareness and concern about antibiotic-resistant strains of Neisseria gonorrhoeae have propelled investments in the R&D of new therapeutic options. In addition, pharmaceutical companies are focusing on the development of novel antibiotics and combination therapies to address this challenge.

Moreover, the implementation of government initiatives and public wellness campaigns aimed at reducing the incidence of sexually transmitted infections (STIs) has significantly enhanced disease surveillance and screening programs, thus boosting the growth of the gonorrhea market. In line with this, advancements in diagnostic technologies, including nucleic acid amplification tests (NAATs), have enhanced the accuracy and speed of gonorrhea detection, leading to earlier and highly effective treatment. Additionally, the rising integration of telemedicine and digital health platforms has facilitated better access to healthcare services and STI testing, particularly in remote and underserved areas. Apart from this, the increasing funding and grants from governmental and non-governmental organizations for STI research and treatment are expected to propel the gonorrhea market in the foreseeable future.

Recent Developments:

• In September 2024, Innoviva Specialty Therapeutics announced that new findings on its investigational drug Zoliflodacin, a first-in-class oral, single-dose antibiotic for treating uncomplicated gonorrhea, will be presented as oral sessions at the 2024 Sexually Transmitted Infections Prevention Conference, taking place from September 16-19, 2024, in Atlanta, GA.
• In April 2024, GSK plc reported positive findings from the crucial Gepotidacin’s EAGLE-1 Phase III trial, a promising first-in-class oral antibiotic with an unprecedented mechanism of action for treating rudimentary urogenital gonorrhea (GC) in adults as well as adolescents. These results are set to be showcased on April 30, 2024, at the ESCMID Global Conference in Barcelona, Spain.

Request for a sample of this report: https://www.imarcgroup.com/gonorrhea-market/requestsample

This report also provides a detailed analysis of the current gonorrhea marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Competitive Landscape with key players:

The competitive landscape of the gonorrhea market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Bayer
2. GSK plc
3. Innoviva

Countries Covered

1. United States
2. Germany
3. France
4. United Kingdom
5. Italy
6. Spain
7. Japan

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145